利什曼原虫疫苗候选佐剂综述。
A review of adjuvants for Leishmania vaccine candidates.
作者信息
Mutiso Joshua M, Macharia John C, Gicheru Michael M
机构信息
Department of Tropical and Infectious Diseases, Institute of Primate Research, National Museums of Kenya, P.O. Box 24481-00502, Karen,Nairobi, Kenya.
出版信息
J Biomed Res. 2010 Jan;24(1):16-25. doi: 10.1016/S1674-8301(10)60004-8.
Abstract
Over the last decade, there has been a flurry of research on adjuvants for vaccines, and several novel adjuvants are now licensed products or in late stage clinical development. The success of adjuvants in enhancing the immune response to antigens has led many researchers to re-focus their vaccine development programs. Although several vaccine candidates have been tested against leishmaniasis, there is yet no effective vaccine against this parasitic disease. Recent research has documented that efforts to develop effective Leishmania vaccine have been limited due to lack of an appropriate adjuvant. In view of this, this review paper outlines some of the adjuvants that have been used in Leishmania vaccine candidates and cites a few of the responses obtained from these studies. The aim of the present review is to consolidate these findings to facilitate the application of these adjuvants in general and experimental vaccinology.
摘要
在过去十年中，针对疫苗佐剂开展了大量研究，目前有几种新型佐剂已成为获批产品或处于临床开发后期阶段。佐剂在增强对抗抗原的免疫反应方面取得的成功，促使许多研究人员重新调整其疫苗开发计划。尽管已有几种候选疫苗针对利什曼病进行了测试，但目前仍没有针对这种寄生虫病的有效疫苗。最近的研究表明，由于缺乏合适的佐剂，开发有效的利什曼原虫疫苗的努力受到了限制。有鉴于此，本文综述概述了一些在利什曼原虫候选疫苗中使用过的佐剂，并列举了这些研究获得的一些反应。本综述的目的是整合这些发现，以促进这些佐剂在一般疫苗学和实验疫苗学中的应用。
相似文献
1
A review of adjuvants for Leishmania vaccine candidates.利什曼原虫疫苗候选佐剂综述。
J Biomed Res. 2010 Jan;24(1):16-25. doi: 10.1016/S1674-8301(10)60004-8.
2
New horizons in adjuvants for vaccine development.疫苗研发佐剂的新视野。
Trends Immunol. 2009 Jan;30(1):23-32. doi: 10.1016/j.it.2008.09.006. Epub 2008 Dec 6.
3
Particulate and non-particle adjuvants in Leishmaniasis vaccine designs: A review.寄生虫和非寄生虫佐剂在利什曼病疫苗设计中的应用：综述。
J Vector Borne Dis. 2023 Apr-Jun;60(2):125-141. doi: 10.4103/0972-9062.361179.
4
Development of nano-carriers for vaccine delivery.纳米载体的疫苗递呈系统开发。
Expert Opin Drug Deliv. 2020 Feb;17(2):167-187. doi: 10.1080/17425247.2020.1713746. Epub 2020 Jan 14.
5
Not All Antigens Are Created Equally: Progress, Challenges, and Lessons Associated with Developing a Vaccine for Leishmaniasis.并非所有抗原都是生来平等的：开发利什曼病疫苗的进展、挑战与经验教训
Clin Vaccine Immunol. 2017 Jul 5;24(7). doi: 10.1128/CVI.00108-17. Print 2017 Jul.
6
Evaluation of the immunoprophylactic potential of a killed vaccine candidate in combination with different adjuvants against murine visceral leishmaniasis.评估一种灭活候选疫苗与不同佐剂联合使用对小鼠内脏利什曼病的免疫预防潜力。
Parasitol Int. 2015 Feb;64(1):70-8. doi: 10.1016/j.parint.2014.10.003. Epub 2014 Oct 12.
7
Visceral leishmaniasis: An overview of vaccine adjuvants and their applications.内脏利什曼病：疫苗佐剂及其应用概述。
Vaccine. 2019 Jun 12;37(27):3505-3519. doi: 10.1016/j.vaccine.2019.04.092. Epub 2019 May 15.
8
Biomarkers of safety and immune protection for genetically modified live attenuated leishmania vaccines against visceral leishmaniasis - discovery and implications.用于治疗内脏利什曼病的基因工程减毒活利什曼原虫疫苗的安全性和免疫保护生物标志物——发现及意义
Front Immunol. 2014 May 23;5:241. doi: 10.3389/fimmu.2014.00241. eCollection 2014.
9
Liposomal adjuvant development for leishmaniasis vaccines.用于利什曼病疫苗的脂质体佐剂研发。
Ther Adv Vaccines. 2017 Aug;5(4-5):85-101. doi: 10.1177/2051013617741578. Epub 2017 Nov 15.
10
The History of Live Attenuated Gene-Deleted Vaccine Candidates.减毒活基因缺失候选疫苗的历史
Pathogens. 2022 Apr 2;11(4):431. doi: 10.3390/pathogens11040431.
引用本文的文献
1
Evaluation of a Novel Multi-Epitope Peptide Vaccine Candidate from LACK, LeIF, GP63, SMT Antigens of in BALB/c Mice.新型多表位肽疫苗候选物对 BALB/c 小鼠中 LACK、LeIF、GP63、SMT 抗原的评价。
Arch Razi Inst. 2022 Dec 31;77(6):2223-2233. doi: 10.22092/ARI.2022.358499.2238. eCollection 2022 Dec.
2
In silico designing of a novel polyvalent multi-subunit peptide vaccine leveraging cross-immunity against human visceral and cutaneous leishmaniasis: an immunoinformatics-based approach.基于免疫信息学的方法：利用针对人体内脏利什曼病和皮肤利什曼病的交叉免疫原性，设计新型多价多亚单位肽疫苗。
J Mol Model. 2023 Mar 16;29(4):99. doi: 10.1007/s00894-023-05503-w.
3
Effects of Selected Adjuvants on Immunogenicity and Protectivity of Bacterin Vaccine in Chickens.佐剂对鸡菌苗免疫原性和保护力的影响。
Arch Razi Inst. 2021 Oct 31;76(4):741-749. doi: 10.22092/ari.2020.343103.1495. eCollection 2021 Oct.
4
A T-Cell Epitope-Based Multi-Epitope Vaccine Designed Using Human HLA Specific T Cell Epitopes Induces a Near-Sterile Immunity against Experimental Visceral Leishmaniasis in Hamsters.一种基于T细胞表位的多表位疫苗，利用人类HLA特异性T细胞表位设计，可诱导仓鼠对实验性内脏利什曼病产生近乎无菌的免疫力。
Vaccines (Basel). 2021 Sep 23;9(10):1058. doi: 10.3390/vaccines9101058.
5
Melittin as a promising anti-protozoan peptide: current knowledge and future prospects.蜂毒肽作为一种有前景的抗寄生虫肽：当前认知与未来展望。
AMB Express. 2021 May 13;11(1):69. doi: 10.1186/s13568-021-01229-1.
6
and Evaluation of Mimetic Peptides as Potential Antigen Candidates for Prophylaxis of Leishmaniosis.以及模拟肽作为利什曼病预防潜在抗原候选物的评估。
Front Chem. 2021 Jan 15;8:601409. doi: 10.3389/fchem.2020.601409. eCollection 2020.
7
Comparison of Protective Potency of DNA and Live Vaccines Expressing A2-CPA-CPB Antigens against Visceral Leishmaniasis in Syrian Hamster as Preliminary Study.表达A2-CPA-CPB抗原的DNA疫苗和活疫苗对叙利亚仓鼠内脏利什曼病保护效力的比较：初步研究
Iran J Parasitol. 2020 Jul-Sep;15(3):383-392. doi: 10.18502/ijpa.v15i3.4203.
8
A new multi-epitope peptide vaccine induces immune responses and protection against Leishmania infantum in BALB/c mice.一种新型多表位肽疫苗诱导 BALB/c 小鼠对利什曼原虫的免疫应答和保护。
Med Microbiol Immunol. 2020 Feb;209(1):69-79. doi: 10.1007/s00430-019-00640-7. Epub 2019 Nov 6.
9
New Insights on the Adjuvant Properties of the Eukaryotic Initiation Factor.真核起始因子的佐剂特性的新见解
J Immunol Res. 2019 Apr 30;2019:9124326. doi: 10.1155/2019/9124326. eCollection 2019.
10
Immunogenicity and Protective Efficacy of T-Cell Epitopes Derived From Potential Th1 Stimulatory Proteins of .潜在 Th1 刺激蛋白的 T 细胞表位的免疫原性和保护效力
Front Immunol. 2019 Feb 28;10:288. doi: 10.3389/fimmu.2019.00288. eCollection 2019.
本文引用的文献
1
New horizons in adjuvants for vaccine development.疫苗研发佐剂的新视野。
Trends Immunol. 2009 Jan;30(1):23-32. doi: 10.1016/j.it.2008.09.006. Epub 2008 Dec 6.
2
Prophylactic efficacy of high-molecular-weight antigenic fractions of a recent clinical isolate of Leishmania donovani against visceral leishmaniasis.杜氏利什曼原虫近期临床分离株的高分子量抗原组分对内脏利什曼病的预防效果
Scand J Immunol. 2008 Nov;68(5):492-501. doi: 10.1111/j.1365-3083.2008.02171.x. Epub 2008 Sep 18.
3
Successful vaccination against Leishmania chagasi infection in BALB/c mice with freeze-thawed Leishmania antigen and Corynebacterium parvum.用冻融的利什曼原虫抗原和短小棒状杆菌对BALB/c小鼠进行成功的抗恰加斯利什曼原虫感染疫苗接种。
Acta Trop. 2007 Nov-Dec;104(2-3):133-9. doi: 10.1016/j.actatropica.2007.08.007. Epub 2007 Aug 31.
4
Immunogenicity of a killed Leishmania vaccine with saponin adjuvant in dogs.含皂苷佐剂的利什曼原虫灭活疫苗在犬类中的免疫原性
Vaccine. 2007 Nov 1;25(44):7674-86. doi: 10.1016/j.vaccine.2007.08.009. Epub 2007 Aug 24.
5
Immune response to leishmania: paradox rather than paradigm.对利什曼原虫的免疫反应：是悖论而非范例。
FEMS Immunol Med Microbiol. 2007 Nov;51(2):229-42. doi: 10.1111/j.1574-695X.2007.00311.x. Epub 2007 Aug 22.
6
Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells.利什-111f，一种重组多蛋白疫苗，通过激发CD4+T细胞来预防内脏利什曼病。
Infect Immun. 2007 Sep;75(9):4648-54. doi: 10.1128/IAI.00394-07. Epub 2007 Jul 2.
7
Immune responses in kala-azar.黑热病中的免疫反应。
Indian J Med Res. 2006 Mar;123(3):245-66.
8
Assessment of transmission-blocking activity of candidate Pvs25 vaccine using gametocytes from chimpanzees.使用来自黑猩猩的配子体评估候选Pvs25疫苗的传播阻断活性。
Am J Trop Med Hyg. 2006 Feb;74(2):215-21.
9
Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial.在一项I期试验中，用Montanide ISA 720佐剂配制的乙型肝炎核心颗粒恶性疟原虫疟疾疫苗的安全性和增强的免疫原性。
Infect Immun. 2005 Jun;73(6):3587-97. doi: 10.1128/IAI.73.6.3587-3597.2005.
10
Second-generation vaccines against leishmaniasis.第二代抗利什曼病疫苗。
Trends Parasitol. 2005 May;21(5):244-9. doi: 10.1016/j.pt.2005.03.006.
Zotero 插件